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Abstract
Cotinine is a principal metabolite of nicotine with a substantially longer half-life, and cotinine levels
in saliva, urine or serum are widely used to validate self-reported smoking status. The nasal cavity
and olfactory system are directly exposed to tobacco smoke in smokers and in non-smokers who
live with or work around smokers. However, despite the potential for a direct impact of tobacco
smoke on the nasal epithelium and olfactory neurons, no prior studies have assessed cotinine levels
in nasal mucus. We sought to determine whether cotinine levels in nasal lavage fluid (NLF) would
provide a reasonable estimate of smoke exposure. We assayed cotinine using a competitive
immunoassay in NLF from 23 smokers, 10 non-smokers exposed to tobacco smoke (ETS) and 60
non-smokers who did not report smoke exposure. NLF cotinine levels were significantly higher in
smokers than in non-smokers, regardless of their exposure to ambient tobacco smoke. Cotinine
levels in this small group of exposed non-smokers were not significantly different than those of non-
exposed non-smokers. A cutoff of 1 ng/ml provided a sensitivity of 91% and a specificity of 99% for
smoking status in this sample. Data were consistent with self-reported smoking status, and a cutoff
of 1.0 ng/ml NLF cotinine may be used to classify smoking status. While saliva is the most easily
obtained body fluid, NLF can be used to provide an objective and precise indication of smoking
status and more directly reflects smoke exposure in the nasal and olfactory mucosa.
Introduction
Precise estimation of direct exposure to tobacco smoke is
a problem for epidemiologic studies due to human errors
and inaccuracy in self report. Assessment of passive expo-
sure to tobacco smoke is even more problematic [1,2].
While nicotine has a relatively short half-life of about 2
hours, cotinine, a principal metabolite of nicotine, has a
half-life of approximately 20 hours, and is a specific and
sensitive marker for determining exposure to tobacco [3-
5]. Therefore, measurement of salivary, urinary or serum
cotinine values have been used to validate self-reported
smoking status [1,4], with saliva providing the most easily
obtained source [6-8].
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Notably, the olfactory sensory neuroepithelium and nasal
mucosa are directly exposed to tobacco smoke in both
smokers and non-smokers who live with or work around
smokers. Smoking has been shown to reduce olfactory
sensitivity in a dose- and time-dependent manner [9-12],
and passive smoke exposure has been implicated in
reduced olfactory function as well [13]. Using nicotine
nasal spray caused adverse effects of nasal irritation and
burning and taste and smell complaints [14]. Moreover,
both exposures to tobacco smoke and to lipopolysaccha-
ride, an active component of cigarette smoke, trigger a dra-
matic increase in the degree of olfactory neuron apoptosis
[15,16].
The impact of smoking on the nasal mucosa has received
considerably less study than its impact on lower respira-
tory tissue. Nonetheless, there is evidence for multiple
deleterious effects, including increased nasal resistance,
decreased mucociliary flow and mucosal sensitivity, and
induces increase in DNA adduct and may cause nasal
tumors due to numerous chemicals found [17,18]. His-
topathological analysis of nasal mucosa obtained from
rats exposed to tobacco smoke revealed a decrease in the
extent of olfactory epithelium including loss of cilia and
development of metaplasia [19].
Tobacco smoke may exert direct effects on nasal epithelial
health and olfactory neuronal function, and proteomic
analysis has demonstrated altered protein levels in the
nasal lavage fluid (NLF) of smokers [20], yet no prior
studies have assessed cotinine levels in nasal mucus. Basic
information concerning cotinine levels in the NLF of indi-
viduals with varying degrees of exposure to tobacco
smoke is of clinical importance for studies evaluating the
impact of tobacco smoke on nasal and olfactory patho-
physiology, as well as in other situations where a nonin-
vasive sample is desired and saliva is not available or
reliable. Therefore, we sought to determine whether coti-
nine levels in NLF would provide a reasonable estimate of
smoke exposure. Our results indicate that NLF cotinine
was significantly higher in smokers than in nonsmokers
and established a cut of 1.0 ng/ml that may be used in
future studies as an objective indicator of current smok-
ing.
Materials and methods
Participants
Individuals (n = 97) who self-reported good general
health participated. All were asked to complete a ques-
tionnaire regarding their smoking status (current smoker,
past smoker, and non-smoker), smoking history (number
of cigarettes or cigars smoked per day), smoking duration
(years), if a past smoker, years since quitting, and ambient
smoke exposure (type and duration). Four participants
were excluded from the analyses: 2 provided inconsistent/
incomplete information regarding their smoking habits,
and 2 reported having recently quit smoking, and thus did
not clearly fall into any of the smoking status groups
described below. The remaining participants included 41
females and 52 males; their mean age was 36.1 ± 11.9
years (range 18–64 years).
Questionnaire content
We used detail questionnaires to determine smoking sta-
tus of subjects. Questions covered age, sex, smoking his-
tory, for smokers only, the number of cigarettes smoked
per day, pipe or cigar smoking, number of years as a regu-
lar smoker. For non-smokers, when did you quit? How
long did you smoke and what did you smoke? Exposure
to environmental tobacco smoke was assessed by the fol-
lowing questions: "Who is currently a smoker, among
people around you?"; "Do you live with someone who
smokes? (Yes/No)"; and "In work place buildings, are you
exposed to other people's tobacco smoke? (Yes/No).
Smoking status groups
Smoker
Twenty-three subjects (8 females, 15 males) reported
themselves to be current smokers. Active smokers con-
sumed between 1 and 20 cigarettes/day at the time of
assessment. Their mean age was 32.3 ± 9.1 years (range
21–64).
Non-smoker non-exposed
Sixtysubjects (27 females, 33 males) reported themselves
to be non-smokers with a minimal history of ambient
exposure to cigarette smoke. If prior smokers, the non-
smokers had not smoked for at least 6 months and were
not subject to substantial exposure to tobacco smoke in
public or private surroundings. Their mean age was 37.9 ±
12.5 years (range 21–63).
Non-smoker exposed to tobacco smoke (ETS)
Ten passive smokers (6 females, 4 males) were defined by
self-reported significant exposure to smoke in public
buildings or private surroundings on a regular basis. Their
mean age was 34.0 ± 12.2 years (range 18–53).
Collection of nasal lavage fluid
Subjects were given a sterilized metered-pump aerosolizer
filled with 0.1 M sterile phosphate buffer solution without
calcium or magnesium. Each pump action delivered 100
μl of solution (4 ml total per nostril). They were asked to
spray and sniff 4–5 times into one nostril while occluding
the other nostril, then to forcibly expel the nasal contents
into a glass container. Collected NLF was then centrifuged
at 9000 rpm for 10 minutes and the supernatant frozen at
-20°C. Freezing NLF samples precipitates the mucins. On
the day of the assay, samples were thawed completely,
vortexed and centrifuged at 1500 × g (@3000 rpm) for 15Tobacco Induced Diseases 2009, 5:11 http://www.tobaccoinduceddiseases.com/content/5/1/11
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minutes. Samples were at room temperature before being
added to the assay plate.
Immunoassay of Cotinine concentration
To determine cotinine levels in NLF, High Sensitivity Sal-
ivary Cotinine Quantitative enzyme immunoassay kit
(Cat. # 1–2112) from The Salimetrics™ was used accord-
ing to manufacturer's instructions with slight modifica-
tion. The test principle for this kit is based on the
competition of cotinine for antibody binding sites. The
cotinine in samples and peroxidase-labeled cotinine com-
pete; therefore the amount of antibody bound to the plate
is inversely proportional to the cotinine concentration.
Briefly, 20 μL of controls (blank and standards) and sam-
ples were pipetted into appropriate wells. First, enzyme
conjugate and, second, antiserum were added and incu-
bated for 1.5 hours at 37°C with constant mixing at 500–
600 rpm. At the end of the incubation period, 3,3',5,5'
Tetramethylbenzidine (TMB) solution was added and
mixed at 500 rpm for 5 minutes and then incubated in the
dark for an additional 25 minutes at room temperature.
The reaction was quenched by adding stop solution using
a multi-channel pipette, followed by mixing on a plate
rotator at room temperature for 3 minutes at 500 rpm (or
until the color turned from green to yellow). The activity
of the peroxidase was determined by a distinct develop-
ment of colors and detected by 450 nm extinction meas-
urement with TMB substrate. The plate was read within 10
minutes of adding stop solution. These analyses took
place at a room temperature between 20 and 25°C. Aver-
age optical density (OD) was calculated by subtracting the
average OD for the non-specific binding wells from the
average OD of the zero standards, controls, and
unknowns. The percent bound (B/Bo) for each standard
(200 ng/mL, 66.7 ng/mL, 22.2 ng/mL, 7.4 ng/mL, 2.5 ng/
mL, and 0.8 ng/mL), control, and unknown was calcu-
lated by dividing the average OD (B) by the average OD
for the zero (Bo). Final OD was converted to ng/ml.
Statistical analysis
All analyses were performed using Systat®, version
11.00.01. Cotinine levels were not normally distributed
(Shapiro-Wilk statistic = 0.54, p < 0.001). Therefore, pair
wise comparisons between groups (smoking status and
gender) were made using the non-parametric Kol-
mogorov-Smirnov Two Sample test. The Spearman corre-
lation was used to assess the relationship between
smoking frequency and NLF cotinine in smokers.
Results
NLF cotinine levels ranged from 0.08 ng/ml to 11.73 ng/
ml and averaged 7.5 times higher in smokers than in non-
smokers. The median cotinine concentration in the NLF
of non-smokers was 0.65 ng/ml (0.08 ng/ml to 0.90 ng/
ml), of passive smokers 0.64 ng/ml (0.54 ng/ml to 1.02
ng/ml) and of active smokers 4.78 ng/ml (0.90 n/ml to
11.73 ng/ml); the percentile distributions of levels in each
group are given in Table 1. Cotinine levels were signifi-
cantly higher in the NLF of smokers than of that of either
non-smokers non-exposed (p < 0.001) or non-smokers
ETS (p < 0.001) (Figure 1). There was, however, no signif-
icant difference in cotinine levels between the latter two
groups. Although others have reported differences
between non-smokers non-exposed and non-smokers ETS
in cotinine levels in serum, saliva and urine [21-25], this
is not a consistent finding, and there tends to be consider-
able overlap between these groups [5,24,25], probably
reflecting, in part, difficulties in quantifying environmen-
tal smoke exposure.
Among non-smoking non-exposed subjects, there was a
small but significant difference between females and
males, with females showing slightly lower cotinine lev-
els, as has been reported by others [23,26]. However, no
significant gender difference was observed in our smaller
groups of passive or active smokers, nor was there a gen-
der difference among smokers in reported frequency of
smoking.
There was a significant correlation (rho = 0.48, p < 0.02)
between reported frequency of cigarette use and measured
NLF cotinine levels in smokers (Figure 2). This is consist-
ent with reports of cotinine levels in saliva and serum
[27,28]. Of note, cotinine levels observed in the two par-
ticipants excluded from the general analyses who reported
recent abstinence from smoking (<3 months) were con-
sistent with, or higher than, their reports of prior usage (1
cigarette/week, cotinine = 1.54 ng/ml; 20 cigarettes/day,
cotinine = 8.37 mg/ml), suggesting either unreported use
of nicotine containing products, misreport of current
usage or slow clearance of cotinine in the nasal mucous.
Based on self-reported smoking status, we estimated the
lowest concentration of cotinine as a cutoff point to dis-
tinguish nonsmokers from smokers. The distributions of
NLF cotinine in smokers and nonsmokers (exposed and
not exposed) overlapped in few subjects. The value of 1
ng/mL represented the best combined levels of sensitivity
(91%) and specificity (99%) (Figure 3). The sum of sensi-
tivity and specificity changed little for cutoff values
between 1 ng/ml (sensitivity, 91%; specificity, 99%) and
2 ng/ml (sensitivity, 74%; specificity, 100%). Similar cut-
off levels were obtained in men and women (not shown).
NLF cotinine levels lower than 1 ng/mL were observed in
100% of the self-reported non-exposed nonsmokers and
in more than 90% of self-reported nonsmokers ETS. In
smokers, fewer than 10 percent of smokers had levels
lower than 1 ng./ml.Tobacco Induced Diseases 2009, 5:11 http://www.tobaccoinduceddiseases.com/content/5/1/11
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Discussion
The effects of tobacco smoke on the xenobiotic enzymes
(cytochrome P-450 system) in the olfactory tissues are of
particular interest because nasal tissues, in particular,
olfactory epithelium, are an initial contact site with
inhaled toxicants. Nicotine is rapidly metabolized to coti-
nine via the cytochrome P450 pathway, which is active
within cells in both the nasal and olfactory epithelia. In
humans nicotine is mainly converted to cotinine by cyto-
chrome P450 (CYP2A) in human olfactory epithelium
[29]. Previous studies demonstrated that cotinine levels
may vary in body fluids in relation to differences in expo-
sure and the activity of xenobiotic metabolizing enzymes
in different tissues and organs [10,15]. The time course of
nicotine in the body organs and resultant pharmacologic
effects are highly dependent on the route and rate of dos-
ing. Nicotine accumulation is age-dependent and is quan-
titatively different in various segments in the mouse brain
[30]. Nicotine also accumulates markedly in different
body fluids such gastric fluid, saliva and breast milk.
Comparison of these gastric fluid/plasma, saliva/plasma
and milk/plasma ratio was found different depend on
administration route [31,32]. Additionally, changes in the
expression of nasal xenobiotic metabolizing enzymes due
to tobacco smoke may have a role in the development of
deficits in olfactory performance. Interestingly, xenobi-
otic-metabolizing enzymines of the nasal mucosae may
be regulated differently than other tissues [33].
Cotinine level is of indicator smoking status Figure 1
Cotinine level is of indicator smoking status. The median cotinine concentration in the NLF of non-smokers was 0.65 ng/
ml, of passive smokers 0.64 ng/ml and of active smokers 4.78 ng/ml. Cotinine levels were significantly higher in the NLF of 
smokers than of that of either non-smokers non-exposed (p < 0.001) or non-smokers ETS (p < 0.001). No significant differ-
ence in cotinine levels between the non-smoker and nonsmoker ETS groups.
Table 1: The percentile distributions of cotinine levels in NLF
Self-reported smoking habit N Min 10th 25th 50th 75th 90th Max
Nonsmokers 60 0.00 0.56 0.59 0.65 0.71 0.76 0.90
Nonsmokers ETS 10 0.54 0.59 0.60 0.64 0.86 0.98 1.02
Smokers 23 0.9 1.11 1.70 4.27 7.51 10.41 11.73Tobacco Induced Diseases 2009, 5:11 http://www.tobaccoinduceddiseases.com/content/5/1/11
Page 5 of 7
(page number not for citation purposes)
Association between the concentration of NLF cotinine and the number of cigarettes reported to be smoked daily Figure 2
Association between the concentration of NLF cotinine and the number of cigarettes reported to be smoked 
daily. Significant correlation was found between reported frequency of cigarette use and measured NLF cotinine levels in 
smokers.
Distribution of NLF cotinine across all subjects Figure 3
Distribution of NLF cotinine across all subjects. NLF cotinine level of 1 ng/mL was lowest concentration as a cutoff point 
to distinguish nonsmokers from smokers with the best combined levels of sensitivity (91%) and specificity (99%). Similar cutoff 
levels were obtained in men and women (not shown). NLF cotinine levels lower than 1 ng/mL were observed in 100% of the 
self-reported non-exposed nonsmokers and in more than 90% of self-reported nonsmokers ETS.Tobacco Induced Diseases 2009, 5:11 http://www.tobaccoinduceddiseases.com/content/5/1/11
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Thus, differences in the levels of cotinine in the nasal
mucus may reflect both exposure to nicotine and the abil-
ity of the nasal detoxification system to metabolize this
xenobiotic chemical. Two major biomarkers for assess-
ment of smoking status, nicotine and cotinine can be
measured in various biological samples, and can be
assayed using gas or liquid chromatography, radioimmu-
noassay (RIA) or enzyme immunoassays (ELISA) [34-37].
However, there has been no report of the whether coti-
nine can be assayed in NLF, and if so, whether levels
reflect smoking status of the subject with sufficient accu-
racy for use in confirmation of smoking status. Our data
provide a reliable protocol and reference criteria for
assignment of smoking status based on cotinine levels in
nasal lavage fluid. In conclusion, NLF cotinine can be a
reliable biomarker of clinical importance in studies evalu-
ating the impact of nicotine exposure on nasal and olfac-
tory pathophysiology, as well as in other situations where
saliva is not available and an objective indicator of smok-
ing status is needed.
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